Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Allarity casts a wider net for stenoparib in ovarian cancer, with no new data yet

The US biotech has amended its mid-stage ovarian cancer study to admit two more kinds of patient, but disclosed no enrolment numbers, endpoints or timelines.

17 Nov 2026 · Allarity Therapeutics, Inc. ALLR · Company news

Allarity Therapeutics has changed the design of its ongoing mid-stage trial of stenoparib, an oral drug that blocks both PARP and tankyrase, so that it now admits more kinds of advanced ovarian cancer patient. The company announced the amendment on 16 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Allarity Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →